Neo-adjuvant radiotherapy in rectal cancer

World Journal of Gastroenterology

Volumn 19, Issue 46, 2013, Pages 8489-8501

  Glimelius, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Chemoradiotherapy; Chemotherapy; Local control; Multidisciplinary; Organ preservation; Radiotherapy; Randomized trials; Rectal cancer

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; UFT;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; FECES INCONTINENCE; HUMAN; MORBIDITY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PRESERVATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; SMALL INTESTINE DISEASE;

CHEMORADIOTHERAPY; CHEMOTHERAPY; LOCAL CONTROL; MULTIDISCIPLINARY; ORGAN PRESERVATION; RADIOTHERAPY; RANDOMIZED TRIALS; RECTAL CANCER;

CHEMORADIOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84890358327     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i46.8489     Document Type: Article

References (102)

1. Birgisson H, Talbäck M, Gunnarsson U, Påhlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol 2005; 31: 845-853 PMID: 15979269 DOI: 10.1016/j.ejso.2005.05.002]
2. den Dulk M, Krijnen P, Marijnen CA, Rutten HJ, van de Poll-Franse LV, Putter H, Meershoek-Klein Kranenbarg E, Jansen-Landheer ML, Coebergh JW, van de Velde CJ. Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy. Eur J Cancer 2008; 44: 1710-1716 PMID: 18573654 DOI: 10.1016/j.ejca.2008.05.004]
3. Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010; 49: 784-796 PMID: 20429731 DOI: 10.3109/02841861003733713]
4. Nedrebø BS, Søreide K, Eriksen MT, Kvaløy JT, Søreide JA, Kørner H. Excess mortality after curative surgery for colorectal cancer changes over time and differs for patients with colon versus rectal cancer. Acta Oncol 2013; 52: 933-940 PMID: 23101468]
5. Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, Maxwell R, Nedrebø B, Påhlman L, Sjövall A, Spigelman A, Engholm G, Gavin A, Gjerstorff ML, Hatcher J, Johannesen TB, Morris E, McGahan CE, Tracey E, Turner D, Richards MA, Coleman MP. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013; 52: 919-932 PMID: 23581611 DOI: 10.3109/0284186X.2 013.764008]
6. Moriya Y, Sugihara K, Akasu T, Fujita S. Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg 1997; 21: 728-732 PMID: 9276704]
7. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304 PMID: 11684209 DOI: 10.1016/S0140-6736(01)06409-1]
8. Glimelius B, Grönberg H, Järhult J, Wallgren A, CavallinStåhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-492 PMID: 14596508 DOI: 10.1080/02841860310012301]
9. Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer a systematic overview. Rev Recent Clin Trials 2008; 3: 204-211 PMID: 18782078 DOI: 10.2174/157488708785700294]
10. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009; (1): CD006041 PMID: 19160264 DOI: 10.1002/14651858. CD006041.pub2]
11. Fiorica F, Cartei F, Licata A, Enea M, Ursino S, Colosimo C, Cammà C. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev 2010; 36: 539-549 PMID: 20334979 DOI: 10.1016/ j.ctrv.2010.03.002]
12. Japanese Society for Cancer of the Colon and Rectum. In: Colorectal carcinoma. Japanese classification. 2th ed. Tokyo: Kanehara, 2009
13. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, Van Cutsem E, Van de Velde C, Cellini N, Latini P. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009; 92: 148-163 PMID: 19595467]
14. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. Br J Surg 2008; 95: 33-49 PMID: 18165939 DOI: 10.1002/bjs.6061]
15. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology 2004; 232: 773-783 PMID: 15273331 DOI: 10.1148/radiol.2323031368]
16. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008; 47: 20-31 PMID: 17957502 DOI: 10.1080/0284186 0701697720]
17. Swartling T, Kälebo P, Derwinger K, Gustavsson B, Kurlberg G. Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer. World J Gastroenterol 2013; 19: 3263-3271 PMID: 23745028 DOI: 10.3748/wjg.v19.i21.3263]
18. Quirke P, Cuvelier C, Ensari A, Glimelius B, Laurberg S, Ortiz H, Piard F, Punt CJ, Glenthoj A, Pennickx F, Seymour M, Valentini V, Williams G, Nagtegaal ID. Evidence-based medicine: the time has come to set standards for staging. J Pathol 2010; 221: 357-360 PMID: 20593493 DOI: 10.1002/path.2720]
19. Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Påhlman L, Quirke P, Valentini V, van de Velde C. Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol 2011; 29: 2142-2143 PMID: 21502560]
20. Valentini V, Glimelius B. Rectal cancer radiotherapy: towards European consensus. Acta Oncol 2010; 49: 1206-1216 PMID: 20843179 DOI: 10.3109/0284186X.2010.506884]
21. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, GlynneJones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516 PMID: 23012255]
22. van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer 2013; 49: 2784-2790 PMID: 23769991]
23. Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Shiozawa M, Yamaguchi T, Moriya Y. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 2012; 13: 616-621 PMID: 22591948 DOI: 10.1016/S1470-2045(12)70158-4]
24. Kusters M, Beets GL, van de Velde CJ, Beets-Tan RG, Marijnen CA, Rutten HJ, Putter H, Moriya Y. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg 2009; 249: 229-235 PMID: 19212175 DOI: 10.1097/ SLA.0b013e318190a664]
25. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450 PMID: 2202842 DOI: 10.1001/jama.1990.03450110090034]
26. NCI. Clinical Announcement. Adjuvant therapy of rectal cancer, March 14. National Cancer Institute, Bethesda, Maryland, US, 1991
27. Glimelius B. Chemoradiotherapy for rectal cancer--is there an optimal combination? Ann Oncol 2001; 12: 1039-1045 PMID: 11583178]
28. Påhlman L, Glimelius B, Graffman S. Preversus postoperative radiotherapy in rectal carcinoma: an interim report from a randomized multicentre trial. Br J Surg 1985; 72: 961-966 PMID: 3910157]
29. Påhlman L, Glimelius B. Preor postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990; 211: 187-195 PMID: 2405793]
30. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740 PMID: 15496622 DOI: 10.1056/NEJMoa040694]
31. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-820 PMID: 19269519 DOI: 10.1016/ S0140-6736(09)60484-0]
32. Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997; 37: 281-287 PMID: 9069298 DOI: 10.1016/S0360-3016(96)00510-X]
33. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223 PMID: 16983741 DOI: 10.1002/bjs.5506]
34. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. Randomized trial of short-course radiotherapy versus longcourse chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827-3833 PMID: 23008301 DOI: 10.1200/JCO.2012.42.9597]
35. Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V, Schlag PM. Preoperative shortcourse radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009; 9: 50 PMID: 19200365 DOI: 10.1186/1471-2407-9-50]
36. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer a systematic overview. Acta Oncol 2007; 46: 504-516 PMID: 17497318 DOI: 10.1080/02841860701348670]
37. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625 PMID: 17008704 DOI: 10.1200/JCO.2006.06.7629]
38. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123 PMID: 16971718 DOI: 10.1056/NEJMoa060829]
39. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687-3694 PMID: 18669453 DOI: 10.1200/JCO.2007.15.3858]
40. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579-588 PMID: 22503032]
41. Vestermark LW, Jensen HA, Pfeiffer P. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol 2012; 51: 311-317 PMID: 22248062 DOI: 10.3109/0284186X.2011.652740]
42. Ishihara S, Hayama T, Yamada H, Nozawa K, Matsuda K, Watanabe T. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer. Hepatogastroenterology 2011; 58: 756-762 PMID: 21830385]
43. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Seitz JF, Bedenne L, Juzyna B, Conroy T. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-4565 PMID: 23109696 DOI: 10.1200/ JCO.2012.42.8771]
44. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780 PMID: 21606427]
45. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687 PMID: 22627104]
46. Schmoll J, Haustermans K, Jay Price T, Nordlinger B, Hofheinz R, Daisne J-F, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig C, Zalcberg JR, Tebbutt NC, Mauer ME, Messina CGM, Lutz MP, Van Cutsen E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. J Clin Oncol 2013; 31: Abstr 3531
47. Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry JC, Ryan DP, Arora A, Evans TL, Soori GS, Chu L, Landes RV, Mohiuddin M, Lopa S, Wolmark N. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29: Abstr 3503
48. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-1627 PMID: 22473163]
49. Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006; 80: 4-12 PMID: 16730086 DOI: 10.1016/j.radonc.2006.04.012]
50. Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol 2009; 48: 343-353 PMID: 18855161 DOI: 10.1080/02841860802 342408]
51. Baatrup G, Endreseth BH, Isaksen V, Kjellmo A, Tveit KM, Nesbakken A. Preoperative staging and treatment options in T1 rectal adenocarcinoma. Acta Oncol 2009; 48: 328-342 PMID: 19180365 DOI: 10.1080/02841860802657243]
52. Gérard JP, Ortholan C, Benezery K, Ginot A, Hannoun-Levi JM, Chamorey E, Benchimol D, François E. Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002-2006. Int J Radiat Oncol Biol Phys 2008; 72: 665-670 PMID: 18455327 DOI: 10.1016/j.ijrobp.2008.01.030]
53. Dahlberg M, Glimelius B, Påhlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg 1999; 229: 493-497 PMID: 10203081]
54. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646 PMID: 11547717 DOI: 10.1056/NEJMoa010580]
55. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650 PMID: 16110023 DOI: 10.1200/JCO.2005.08.144]
56. Radu C, Berglund A, Påhlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer a retrospective study. Radiother Oncol 2008; 87: 343-349 PMID: 18093674 DOI: 10.1016/j.radonc.2007.11.025]
57. Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A, Kwok-Williams M, Sebag-Montefiore D. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009; 92: 210-214 PMID: 19409638 DOI: 10.1016/ j.radonc.2009.04.007]
58. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 2012; 99: 577-583 PMID: 22241246 DOI: 10.1002/bjs.7796]
59. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-717; discussion 711-717 PMID: 15383798 DOI: 10.1097/01.sla.0000141194.27992.32]
60. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007; 25: 1014-1020 PMID: 17350952 DOI: 10.1200/JCO.2006.09.7840]
61. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010; 53: 1692-1698 PMID: 21178866 DOI: 10.1007/DCR.0b013e3181f42b89]
62. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewé KW, Buijsen J, Beets GL. Wait-andsee policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011; 29: 4633-4640 PMID: 22067400 DOI: 10.1200/JCO.2011.37.7176]
63. Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemoradiotherapy? Acta Oncol 2010; 49: 378-381 PMID: 20151936 DOI: 10.3109/02841860903483692]
64. Hingorani M, Hartley JE, Greenman J, Macfie J. Avoiding radical surgery after pre-operative chemoradiotherapy: a pos sible therapeutic option in rectal cancer? Acta Oncol 2012; 51: 275-284 PMID: 22150079 DOI: 10.3109/0284186X.2011.63 6756]
65. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, De Neve W. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1129-1142 PMID: 16750329 DOI: 10.1016/ j.ijrobp.2006.02.050]
66. Ippolito E, Mertens I, Haustermans K, Gambacorta MA, Pasini D, Valentini V. IGRT in rectal cancer. Acta Oncol 2008; 47: 1317-1324 PMID: 18661433 DOI: 10.1080/02841860802256459]
67. Caravatta L, Padula GD, Picardi V, Macchia G, Deodato F, Massaccesi M, Sofo L, Pacelli F, Rotondi F, Cecere G, Sallustio G, Di Lullo L, Piscopo A, Mignogna S, Bonomo P, Cellini N, Valentini V, Morganti AG. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol 2011; 50: 1151-1157 PMID: 21851185 DOI: 10.3109 /0284186X.2011.582880]
68. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 2012; 84: 949-954 PMID: 22592048 DOI: 10.1016/j.ijrobp.2012.02.006.]
69. Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B. Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta Oncol 2013; 52: 528-537 PMID: 23113591 DOI: 10.3109/0284186X.2012.737022]
70. Syk E, Torkzad MR, Blomqvist L, Ljungqvist O, Glimelius B. Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer. Br J Surg 2006; 93: 113-119 PMID: 16372254 DOI: 10.1002/bjs.5233]
71. Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys 2008; 72: 658-664 PMID: 18495376 DOI: 10.1016/j.ijrobp.2008.01.063]
72. Nijkamp J, Kusters M, Beets-Tan RG, Martijn H, Beets GL, van de Velde CJ, Marijnen CA. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys 2011; 80: 103-110 PMID: 20646849]
73. Kusters M, Wallner C, Lange MM, DeRuiter MC, van de Velde CJ, Moriya Y, Rutten HJ. Origin of presacral local recurrence after rectal cancer treatment. Br J Surg 2010; 97: 1582-1587 PMID: 20641063 DOI: 10.1002/bjs.7180]
74. Wang C, Zhou ZG, Yu YY, Li Y, Lei WZ, Cheng Z, Chen ZX. Patterns of lateral pelvic lymph node metastases and micrometastases for patients with lower rectal cancer. Eur J Surg Oncol 2007; 33: 463-467 PMID: 17081722 DOI: 10.1016/ j.ejso.2006.09.015]
75. Taylor N, Crane C, Skibber J, Feig B, Ellis L, Vauthey JN, Hamilton S, Cleary K, Dubrow R, Brown T, Wolff R, Hoff P, Sanfilippo N, Janjan N. Elective groin irradiation is not indicated for patients with adenocarcinoma of the rectum extending to the anal canal. Int J Radiat Oncol Biol Phys 2001; 51: 741-747 PMID: 11597817 DOI: 10.1016/S0360-3016(01)]
76. West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol 2008; 26: 3517-3522 PMID: 18541901 DOI: 10.1200/JCO.2007.14.5961]
77. Bakx R, Emous M, Legemate DA, Zoetmulder FA, van Tienhoven G, Bemelman WA, van Lanschot JJ. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol 2006; 32: 520-526 PMID: 16600560 DOI: 10.1016/j.ejso.2006.02.023]
78. Nyström H, Blomqvist E, Høyer M, Montelius A, Muren LP, Nilsson P, Taheri-Kadkhoda Z, Glimelius B. Particle therapy a next logical step in the improvement of radiotherapy. Acta Oncol 2011; 50: 741-744 PMID: 21767169 DOI: 10.3109/02841 86X.2011.590150]
79. Schippers JM, Lomax AJ. Emerging technologies in proton therapy. Acta Oncol 2011; 50: 838-850 PMID: 21767183 DOI: 10.3109/0284186X.2011.582513]
80. Maggiulli E, Fiorino C, Passoni P, Broggi S, Gianolini S, Salvetti C, Slim N, Di Muzio NG, Calandrino R. Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: implications for adaptive dose escalation strategies. Acta Oncol 2012; 51: 318-324 PMID: 22497434 DOI: 10.3109/0284186X.2012.66635 8]
81. Alevronta E, Lind H, Al-Abany M, Waldenström AC, Olsson C, Dunberger G, Mavroidis P, Nyberg T, Johansson KA, Avall-Lundqvist E, Steineck G, Lind BK. Dose-response relationships for an atomized symptom of fecal incontinence after gynecological radiotherapy. Acta Oncol 2013; 52: 719-726 PMID: 23113592 DOI: 10.3109/0284186X.2012.734924]
82. Tiv M, Puyraveau M, Mineur L, Calais G, Maingon P, Bardet E, Mercier M, Bosset JF. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother 2010; 14: 530-534 PMID: 20797891]
83. Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. Int J Radiat Oncol Biol Phys 2011; 81: 1017-1024 PMID: 20932687 DOI: 10.1016/j.ijrobp.2010.07.007]
84. Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B. Health-related quality of life (HRQoL) after multimodal treatment for primarily nonresectable rectal cancer. Long-term results from a phase III study. Eur J Cancer 2012; 48: 813-819 PMID: 21782418]
85. Påhlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Ojerskog B, Damber L, Johansson R. The Swedish rectal cancer registry. Br J Surg 2007; 94: 1285-1292 PMID: 17661309 DOI: 10.1002/bjs.5679]
86. Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, Langmark F, Myrvold HE, Søreide O. A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002; 45: 857-866 PMID: 12130870]
87. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, Nagtegaal ID, Rutten HJ, van de Velde CJ, Wiggers T, Hospers GA, Havenga K. Evaluation of shortcourse radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013; 24: 1762-1769 PMID: 23524865 DOI: 10.1093/annonc/ mdt124]
88. Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B. Shortcourse radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 2013; 13: 279 PMID: 23742033 DOI: 10.1186/1471-2407-13-279]
89. Glimelius B. Adjuvant chemotherapy. Eur J Cancer Suppl 2013; 11: 72-79 [DOI: 10.1016/j.ejcsup.2013.07.034]
90. Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, Malinowska M, Krynski J, Kosakowska E, Rutkowski A, Pietrzak L, Kepka L, Radziszewski J, Olszyna-Serementa M, Bujko M, Danek A, Kryj M, Wydmanski J, Zegarski W, Markiewicz W, Lesniak T, Zygulski I, Porzuczek-Zuziak D, Bebenek M, Maciejczyk A, Polkowski W, Czeremszynska B, Cieslak-Zeranska E, Toczko Z, Radkowski A, Kolodziejski L, Szczepkowski M, Majewski A, Jankowski M. Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 2013; 107: 171-177 PMID: 23590986 DOI: 10.1016/j.radonc.2013.03.001]
91. Duncan W, Smith AN, Freedman LS, Alderson MR, Arnott SJ, Bleehen NM. The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer; results of a randomly controlled trial. Br J Surg 1984; 71: 21-25 PMID: 6360300]
92. Gérard A, Buyse M, Nordlinger B, Loygue J, Pène F, Kempf P, Bosset JF, Gignoux M, Arnaud JP, Desaive C. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988; 208: 606-614 PMID: 3056288]
93. Horn A, Halvorsen JF, Dahl O. Preoperative radiotherapy in operable rectal cancer. Dis Colon Rectum 1990; 33: 823-828 PMID: 2209270]
94. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Rectal Cancer Study Group. Cancer 1990; 66: 49-55 PMID: 2191763]
95. Frykholm GJ, Glimelius B, Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36: 564-572 PMID: 8500374]
96. Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course lowdose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur J Cancer 1994; 30A: 1602-1606 PMID: 7530469]
97. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996; 348: 1605-1610 PMID: 8961989 DOI: 10.1016/S0140-6736(96)05348-2]
98. Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis Colon Rectum 1994; 37: 1205-1214 PMID: 7995145]
99. Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 2001; 92: 896-902 PMID: 11550163]
100. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-1933 PMID: 22529255]
101. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582 PMID: 21596621]
102. Blomqvist L, Glimelius B. The 'good', the 'bad', and the 'ugly' rectal cancers. Acta Oncol 2008; 47: 5-8 PMID: 18097776]